Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$0.23 - $0.46 $52,348 - $104,696
-227,601 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$0.3 - $0.61 $8,225 - $16,725
-27,419 Reduced 10.75%
227,601 $97,000
Q4 2021

Feb 10, 2022

SELL
$0.55 - $1.04 $2,506 - $4,740
-4,558 Reduced 1.76%
255,020 $140,000
Q3 2021

Nov 12, 2021

BUY
$1.06 - $1.52 $8,043 - $11,533
7,588 Added 3.01%
259,578 $275,000
Q2 2021

Aug 05, 2021

BUY
$1.22 - $1.65 $124,997 - $169,054
102,457 Added 68.52%
251,990 $381,000
Q1 2021

May 06, 2021

BUY
$1.18 - $2.62 $50,026 - $111,074
42,395 Added 39.57%
149,533 $230,000
Q4 2020

Feb 10, 2021

BUY
$1.05 - $2.24 $63,554 - $135,582
60,528 Added 129.86%
107,138 $112,000
Q3 2020

Nov 12, 2020

BUY
$1.7 - $6.41 $3,553 - $13,396
2,090 Added 4.69%
46,610 $95,000
Q2 2020

Aug 13, 2020

BUY
$0.87 - $2.46 $38,732 - $109,519
44,520 New
44,520 $99,000

About iBio, Inc.


  • Ticker IBIO
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,006,580
  • Market Cap $24M
  • Description
  • iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for t...
More about IBIO
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.